Canada 
Alberta 
British Columbia 
Manitoba
New Brunswick 
Newfoundland Labrador 
Nova Scotia 
Ontario 
Prince Edward Island 
Quebec 
Saskatchewan 
United States 
Belgium
France 
Italy 
Switzerland
Elsewhere
Elsewhere
×
Elsewhere
Elsewhere
Semaglutide: The Pros and Cons of This Medicine
Conclusion
Semaglutide and GLP-1 receptor agonists should be considered as a complement to a healthy lifestyle, including a balanced diet and physical activity. These medications have demonstrated positive effects on glycated hemoglobin and cardiovascular health. However, the observed weight loss can be difficult to maintain when stopping the treatment. Also, one must not lose sight of the side effects that can be bothersome enough to cause treatment discontinuation. Finally, to prevent the potential loss of muscle mass, physical activity and adequate protein intake must be part of the equation. Support strategies must be implemented to maximize the drug’s potential while minimizing potential risks. These can take the form of group meetings, individual consultations with dietitians, or even digital platform services. Future studies are still needed to determine the most appropriate management protocol.
SOSCuisine offers weekly meal plans, all based on the Mediterranean diet, and customizable according to allergies, intolerances, and individual preferences. Some meal plans are specifically designed for metabolic conditions and weight loss. Should you need more support, we do offer consultations with registered dietitians, that will help you find the approach that best suits your needs.
Sources
1. Canada’s Drug Agency | CDA-AMC, https://www.cda-amc.ca/, accessed on 2025-05-16
2. Papakonstantinou I, Tsioufis K, Katsi V. Spotlight on the Mechanism of Action of Semaglutide. Curr Issues Mol Biol. 2024 Dec 23;46(12):14514-14541. doi: 10.3390/cimb46120872. PMID: 39728000; PMCID: PMC11674233.
3. Andreadis P, Karagiannis T, Malandris K, et al. Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis. Diabetes Obes Metab. 2018 Sep;20(9):2255-2263. doi: 10.1111/dom.13361. Epub 2018 Jun 10. PMID: 29756388.
4. Yang Y, He L, Han S, et al. Sex Differences in the Efficacy of Glucagon-Like Peptide-1 Receptor Agonists for Weight Reduction: A Systematic Review and Meta-Analysis. J Diabetes. 2025 Mar;17(3):e70063. doi: 10.1111/1753-0407.70063. PMID: 40040445; PMCID: PMC11880690.
5. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022 Aug;24(8):1553-1564. doi: 10.1111/dom.14725. Epub 2022 May 19. PMID: 35441470; PMCID: PMC9542252.
6. Yin Y, Zhang M, Cao Q, et al. Efficacy of GLP-1 Receptor Agonist-Based Therapies on Cardiovascular Events and Cardiometabolic Parameters in Obese Individuals Without Diabetes: A Meta-Analysis of Randomized Controlled Trials. J Diabetes. 2025 Apr;17(4):e70082. doi: 10.1111/1753-0407.70082. PMID: 40207414; PMCID: PMC11982705.
7. Rivera FB, Chin MNC, Pine PLS, et al. Glucagon-like peptide 1 receptor agonists modestly reduced low-density lipoprotein cholesterol and total cholesterol levels independent of weight reduction: a meta-analysis and meta-regression of placebo controlled randomized controlled trials. Curr Med Res Opin. 2025 Jan;41(1):185-197. doi: 10.1080/03007995.2024.2442027. Epub 2024 Dec 18. PMID: 39666879.
8. Zhang YS, Zheng YD, Yuan Y, et al. Effects of Anti-Diabetic Drugs on Fracture Risk: A Systematic Review and Network Meta-Analysis. Front Endocrinol (Lausanne). 2021 Oct 14;12:735824. doi: 10.3389/fendo.2021.735824. PMID: 34721294; PMCID: PMC8553257.
9. Au HCT, Zheng YJ, Le GH, et al. Association of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and neurogenesis: a systematic review. Acta Neuropsychiatr. 2025 Feb 14;37:e50. doi: 10.1017/neu.2025.4. PMID: 39950609.
10. Arillotta D, Floresta G, Papanti Pelletier GD, et al. Exploring the Potential Impact of GLP-1 Receptor Agonists on Substance Use, Compulsive Behavior, and Libido: Insights from Social Media Using a Mixed-Methods Approach. Brain Sci. 2024 Jun 20;14(6):617. doi: 10.3390/brainsci14060617. PMID: 38928616; PMCID: PMC11202225.
11. Esparham A, Mehri A, Dalili A, et al. Safety and efficacy of glucagon-like peptide-1 (GLP-1) receptor agonists in patients with weight regain or insufficient weight loss after metabolic bariatric surgery: A systematic review and meta-analysis. Obes Rev. 2024 Nov;25(11):e13811. doi: 10.1111/obr.13811. Epub 2024 Aug 12. PMID: 39134066.
12. Yao H, Zhang A, Li D, et al. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ. 2024 Jan 29;384:e076410. doi: 10.1136/bmj-2023-076410. PMID: 38286487; PMCID: PMC10823535.
13. Safwan M, Bourgleh MS, Alotaibi SA, et al. Gastrointestinal safety of semaglutide and tirzepatide vs. placebo in obese individuals without diabetes: a systematic review and meta analysis. Ann Saudi Med. 2025 Mar-Apr;45(2):129-143. doi: 10.5144/0256-4947.2025.129. Epub 2025 Apr 3. PMID: 40189856.
14. Bikou A, Dermiki-Gkana F, Penteris M, et al. A systematic review of the effect of semaglutide on lean mass: insights from clinical trials. Expert Opin Pharmacother. 2024 Apr;25(5):611-619. doi: 10.1080/14656566.2024.2343092. Epub 2024 Apr 18. PMID: 38629387.
15. Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity (Silver Spring). 2025 May 30. doi: 10.1002/oby.24336. Epub ahead of print. PMID: 40445127
16. Pak KY, Cutri RM, Nadeem W, et al.. GLP-1 Receptor Agonist Induced Eustachian Tube Dysfunction: Database and Systematic Review of Otolaryngologic Adverse Events. Otol Neurotol. 2025 Jan 1;46(1):19-22. doi: 10.1097/MAO.0000000000004373. PMID: 39666743.
17. Arrowaili A. Efficacy and Safety of GLP- 1 Receptor Agonists in the Management of Weight Recurrence or Suboptimal Clinical Response after Undergoing Metabolic Bariatric Surgeries: A Meta-Analysis. Obes Surg. 2025 May;35(5):1947-1960. doi: 10.1007/s11695-025-07856-y. Epub 2025 Apr 16. PMID: 40237975.
Author
A University of Montreal graduate and holding a Master's Degree in Medical Research from Griffith University in Australia, Tracy is a Registered Dietitian and active member of the Ordre professionnel des Diététistes Nutritionnistes du Québec (ODNQ). With more than 15 years of experience, she likes to share her knowledge about food in a simple and illustrated way in order to support you in achieving your health goals. Her approach combines the pleasure of eating, intuitive eating and mindfulness. Tracy specializes in adapted nutrition for chronic diseases, weight loss, gastrointestinal health, vegetarianism and veganism.
Leave a Reply